linc00958/miR-185-5p/RSF-1 modulates cisplatin resistance and angiogenesis through AKT1/GSK3β/VEGFA pathway in cervical cancer

Tian, Jing; Cheng, Lei; Kong, Enqi; Gu, Wenjin; Jiang, Yuanyuan; Qin, Hao; Kong, Beihua; Sun, Li

doi:10.1186/s12958-022-00995-2

Cited by 20 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is interesting to note that KEGG pathway enrichment was observed only in the downregulated group (Figure 5F; Table S3). Among these enrichments, some signaling pathways were commonly related to cisplatin resistance in osteosarcomas, such as the mitogen‐activated protein kinase (MAPK) pathway 20‐24 and vascular endothelial growth factor (VEGF) 25‐27 . Additionally, 10 hub genes were identified, and their associated signaling pathways were demonstrated (Figure 5G).…”

Section: Resultsmentioning

confidence: 98%

“…Among these enrichments, some signaling pathways were commonly related to cisplatin resistance in osteosarcomas, such as the mitogen‐activated protein kinase (MAPK) pathway 20 , 21 , 22 , 23 , 24 and vascular endothelial growth factor (VEGF). 25 , 26 , 27 Additionally, 10 hub genes were identified, and their associated signaling pathways were demonstrated (Figure 5G ). These hub genes also appeared to play a regulatory role in reducing cisplatin resistance when ITGB3 was knocked out (Figure 5G ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

ITGB3 promotes cisplatin resistance in osteosarcoma tumors

Chen

Jiang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Objective Osteosarcoma is the most malignant and common primary bone tumor with a high rate of recurrence that mainly occurs in children and young adults. Therefore, it is vital to facilitate the development of novel effective therapeutic means and improve the overall prognosis of osteosarcoma patients via a deeper understanding of the mechanisms of chemoresistance in osteosarcoma progression. Methods In this research, the relationship between ITGB3 and the clinical characteristics of patients was detected through analysis of publicly available clinical datasets. The expression of ITGB3 was analysis in collected human osteosarcoma tissues. In addition, the potential functions of ITGB3 in the cisplatin resistance of osteosarcoma cells were investigated in vitro and in tumor xenotransplantation. Finally, the molecular mechanism of ITGB3 in the progression and recurrence of osteosarcoma were explored via transcriptome analysis. Results ITGB3 was identified as a potential regulator of tumorigenicity and cisplatin resistance in relapsed osteosarcoma. Furthermore, the decreased osteosarcoma cell proliferation and migration ability in ITGB3 knockout osteosarcoma cells were related to increased apoptosis and slowing cell cycle progression. In addition, ITGB3 had a positive correlation with cisplatin resistance in cells and tumor xenografts in mice. Accordingly, ITGB3 performed the functions of proliferation and cisplatin resistance in osteosarcoma through the MAPK and VEGF signaling pathways. Conclusion Our results will contribute to a better understanding of the function and mechanism of ITGB3 in osteosarcoma cisplatin resistance and provide a novel therapeutic target to decrease cisplatin resistance and tumor recurrence in osteosarcoma patients.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%

ITGB3 promotes cisplatin resistance in osteosarcoma tumors

Chen

Jiang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Moreover, linc00958 expression was correlated with a short survival in cervical cancer patients. Mechanistically, linc00958 regulated miR-185-5p and RSF-1 and modulated cisplatin resistance in cervical cancer cells via targeting AKT1/GSK3β/VEGFA pathway ( Tian et al, 2022 ). Depletion of lncRNA NCK1-AS1 promoted cisplatin sensitivity to cisplatin via modulating miR-134-5p and restoring the expression of MSH2 in cervical cancer ( Zhang et al, 2019 ).…”

Section: Other Lncrnas Regulate Drug Resistancementioning

confidence: 99%

The role of long noncoding RNAs in therapeutic resistance in cervical cancer

Zhou

Liu

Wang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cervical cancer is one of the common tumors and often causes cancer-related death in women. Chemotherapy is a common cancer therapy, which displays a pivotal clinical benefit for cancer patients. However, chemoresistance becomes a big obstacle for failure of treatment in cancer patients. Recently, long noncoding RNAs (lncRNAs) have been identified to regulate drug resistance in human cancers, including cervical cancer. In this review, we describe the role of lncRNAs in regulation of chemotherapeutic resistance in cervical cancer. We also discuss the molecular mechanisms of lncRNA-mediated drug resistance in cervical cancer. Moreover, we describe that targeting lncRNAs could reverse drug resistance in cervical cancer. Therefore, lncRNAs could become effective therapeutic targets and chemotherapeutic sensitizers for cervical cancer patients.

show abstract

“…Moreover, an increasing number of studies have demonstrated that lncRNAs may participate in the regulation of DDP sensitivity in cervical cancer. For example, Tian et al reported that linc00958 expression was upregulated in DDP-resistant cervical cancer cells, and linc00958/miR-185-5p/RSF-1 contributed to DDP resistance and angiogenesis through AKT1/GSK3β/VEGFA signaling in cervical cancer (Tian et al, 2022). In addition, Liu et al provided the evidence that lncRNA NNT-AS1 facilitated DDP resistance of cervical cancer by targeting miR-186/HMGB1 signaling cascade (Liu et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

“…For example, Tian et al. reported that linc00958 expression was upregulated in DDP‐resistant cervical cancer cells, and linc00958/miR‐185‐5p/RSF‐1 contributed to DDP resistance and angiogenesis through AKT1/GSK3β/VEGFA signaling in cervical cancer (Tian et al., 2022). In addition, Liu et al.…”

Section: Introductionmentioning

confidence: 99%

LINC00460 knockdown sensitizes cervical cancer to cisplatin by downregulating TGFBI

Tian,

Feng,

Tao

2023

Chem Biol Drug Des

View full text Add to dashboard Cite

The acquired resistance of cancer to cisplatin (DDP) limits the efficacy of chemotherapy. The prognostic value of long noncoding RNA (lncRNA) LINC00460 has been reported in cervical cancer. However, its effect on DDP sensitivity in cervical cancer remains poorly understood. In present study, LINC00460 was screened out through bioinformatics analysis. The expression levels of mRNAs and proteins were measured by reverse transcription‐quantitative PCR (RT‐qPCR) or western blot analysis. The sensitivity to DDP was investigated using an CCK8 assay. Cell apoptosis was determined by flow cytometry. The differentially expressed genes that were associated with the poor prognosis of cervical cancer were screened, and their correlations with LINC00460 expression were explored using Pearson's correlation analysis. Tumor xenograft model was used to assess the effect of LINC00460 knockdown on DDP sensitivity in vivo. The interaction between miR‐338‐3p and LINC00460 or transforming growth factor β‐induced protein (TGFBI) was confirmed by RNA immunoprecipitation (RIP) and luciferase reporter assays. LINC00460 expression was increased in cervical cancer tissues and cells. High expression of LINC00460 was associated with dismal prognosis in cervical cancer patients. Silencing of LINC00460 increased drug sensitivity and induced apoptosis in DDP‐resistant‐cervical cancer cells. LINC00460 knockdown enhanced DDP sensitivity in cervical cancer cells largely by downregulating TGFBI expression. LINC00460 knockdown enhanced the sensitivity of cervical cancer to DDP in vivo, and this effect was partly mediated by the downregulation of TGFBI. LINC00460 positively regulated TGFBI expression, possibly by acting as a sponge of miR‐338‐3p. LINC00460 knockdown contributed to DDP sensitivity of cervical cancer by downregulating TGFBI, providing a novel mechanism underlying the acquisition of DDP sensitivity.

show abstract

linc00958/miR-185-5p/RSF-1 modulates cisplatin resistance and angiogenesis through AKT1/GSK3β/VEGFA pathway in cervical cancer

Cited by 20 publications

References 45 publications

ITGB3 promotes cisplatin resistance in osteosarcoma tumors

ITGB3 promotes cisplatin resistance in osteosarcoma tumors

The role of long noncoding RNAs in therapeutic resistance in cervical cancer

LINC00460 knockdown sensitizes cervical cancer to cisplatin by downregulating TGFBI

Contact Info

Product

Resources

About